Acne Vulgaris (Dermatology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris – Drugs In Development, 2021, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 18, 6, 1, 19, 5 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Akaal Pharma Pty Ltd

Allianz Pharmascience Ltd (Inactive)

AMD Therapeutics LLC

Amgen Inc

AnaptysBio Inc

AOBiome LLC

Atacama Therapeutics Inc

Attillaps Holdings Inc

Avecho Biotechnology Ltd

Avicanna Inc

Bausch Health Companies Inc

Biofrontera AG

Biozeus Pharmaceutical SA

Boston Pharmaceuticals Inc

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Cassiopea SpA

Cellix Bio Pvt Ltd

Claritas Pharmaceuticals Inc

Clinuvel Pharmaceuticals Ltd

Cutanea Life Sciences Inc

Daewoong Pharmaceutical Co Ltd

Dermata Therapeutics Inc

Dermavant Sciences Inc

Devonian Health Group Inc

Eligo Bioscience SA

ELORAC Inc

Hoth Therapeutics Inc

Innovation Pharmaceuticals Inc

Kintor Pharmaceutical Ltd

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Maruho Co Ltd

Matrisys Bioscience Inc

Melinta Therapeutics Inc

Naked Biome Inc

Novabiotics Ltd

Novartis AG

Origimm Biotechnology GmbH

Ortho Dermatologics Inc

Paratek Pharmaceuticals Inc

Phagelux Inc

PHI Therapeutics Inc

Promius Pharma LLC

Provectus Biopharmaceuticals Inc

Revive Therapeutics Ltd

Riptide Bioscience Inc

SaNOtize Research and Development Corp

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Timber Pharmaceuticals Inc

Verge Therapeutics Inc

VYNE Therapeutics Inc

Vyome Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Acne Vulgaris - Overview

Acne Vulgaris - Therapeutics Development

Acne Vulgaris - Therapeutics Assessment

Acne Vulgaris - Companies Involved in Therapeutics Development

Acne Vulgaris - Drug Profiles

Acne Vulgaris - Dormant Projects

Acne Vulgaris - Discontinued Products

Acne Vulgaris - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Acne Vulgaris, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Acne Vulgaris – Pipeline by Akaal Pharma Pty Ltd, 2021

Acne Vulgaris – Pipeline by Allianz Pharmascience Ltd (Inactive), 2021

Acne Vulgaris – Pipeline by AMD Therapeutics LLC, 2021

Acne Vulgaris – Pipeline by Amgen Inc, 2021

Acne Vulgaris – Pipeline by AnaptysBio Inc, 2021

Acne Vulgaris – Pipeline by AOBiome LLC, 2021

Acne Vulgaris – Pipeline by Atacama Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by Attillaps Holdings Inc, 2021

Acne Vulgaris – Pipeline by Avecho Biotechnology Ltd, 2021

Acne Vulgaris – Pipeline by Avicanna Inc, 2021

Acne Vulgaris – Pipeline by Bausch Health Companies Inc, 2021

Acne Vulgaris – Pipeline by Biofrontera AG, 2021

Acne Vulgaris – Pipeline by Biozeus Pharmaceutical SA, 2021

Acne Vulgaris – Pipeline by Boston Pharmaceuticals Inc, 2021

Acne Vulgaris – Pipeline by Botanix Pharmaceuticals Ltd, 2021

Acne Vulgaris – Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2021

Acne Vulgaris – Pipeline by Cassiopea SpA, 2021

Acne Vulgaris – Pipeline by Cellix Bio Pvt Ltd, 2021

Acne Vulgaris – Pipeline by Claritas Pharmaceuticals Inc, 2021

Acne Vulgaris – Pipeline by Clinuvel Pharmaceuticals Ltd, 2021

Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, 2021

Acne Vulgaris – Pipeline by Daewoong Pharmaceutical Co Ltd, 2021

Acne Vulgaris – Pipeline by Dermata Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by Dermavant Sciences Inc, 2021

Acne Vulgaris – Pipeline by Devonian Health Group Inc, 2021

Acne Vulgaris – Pipeline by Eligo Bioscience SA, 2021

Acne Vulgaris – Pipeline by ELORAC Inc, 2021

Acne Vulgaris – Pipeline by Hoth Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by Innovation Pharmaceuticals Inc, 2021

Acne Vulgaris – Pipeline by Kintor Pharmaceutical Ltd, 2021

Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021

Acne Vulgaris – Pipeline by Madam Therapeutics BV, 2021

Acne Vulgaris – Pipeline by Maruho Co Ltd, 2021

Acne Vulgaris – Pipeline by Matrisys Bioscience Inc, 2021

Acne Vulgaris – Pipeline by Melinta Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by Naked Biome Inc, 2021

Acne Vulgaris – Pipeline by Novabiotics Ltd, 2021

Acne Vulgaris – Pipeline by Novartis AG, 2021

Acne Vulgaris – Pipeline by Origimm Biotechnology GmbH, 2021

Acne Vulgaris – Pipeline by Ortho Dermatologics Inc, 2021

Acne Vulgaris – Pipeline by Paratek Pharmaceuticals Inc, 2021

Acne Vulgaris – Pipeline by Phagelux Inc, 2021

Acne Vulgaris – Pipeline by PHI Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by Promius Pharma LLC, 2021

Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, 2021

Acne Vulgaris – Pipeline by Revive Therapeutics Ltd, 2021

Acne Vulgaris – Pipeline by Riptide Bioscience Inc, 2021

Acne Vulgaris – Pipeline by SaNOtize Research and Development Corp, 2021

Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021

Acne Vulgaris – Pipeline by Timber Pharmaceuticals Inc, 2021

Acne Vulgaris – Pipeline by Verge Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by VYNE Therapeutics Inc, 2021

Acne Vulgaris – Pipeline by Vyome Therapeutics Inc, 2021

Acne Vulgaris – Dormant Projects, 2021

Acne Vulgaris – Dormant Projects, 2021 (Contd..1)

Acne Vulgaris – Dormant Projects, 2021 (Contd..2)

Acne Vulgaris – Dormant Projects, 2021 (Contd..3)

Acne Vulgaris – Dormant Projects, 2021 (Contd..4)

Acne Vulgaris – Dormant Projects, 2021 (Contd..5)

Acne Vulgaris – Dormant Projects, 2021 (Contd..6)

Acne Vulgaris – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Acne Vulgaris, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports